Oncocross Therapeutics to expand anticancer and obesity drug development based on Jacuzbo royalties
Predicted impact: Low
Routine shareholder meeting notices already reported.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.